Related Experiment Video
Updated: Feb 20, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Checkpoint Inhibition in Non-Hodgkin's Lymphoma
1Department of Hematology, Oncology and Pneumology and University Cancer Center Mainz, University Medical School of the Johannes Gutenberg University, Mainz, Germany.
Abstract:
As patients continue to die from malignant lymphoma, novel treatment options continue to be warranted. To successfully grow and spread, tumor cells need to escape the immune system; therefore, the augmentation or restoration of immune effectors against the malignant cell could be of great value, as shown, e.g., for allogeneic transplantation. A deepened understanding of the regulation of activation and inhibition of the T cell-based effector mechanisms has led to the development of drugs that are able to modify specific checkpoints of this system and thereby raise an immune response against tumor cells. With dramatic responses observed in Hodgkin's disease (HD), interest has risen to explore these drugs in non-Hodgkin's lymphoma (NHL). Available data underline the potential of checkpoint inhibitors in a variety of lymphoma entities, such as primary mediastinal B cell lymphoma (PMBCL) or central nervous system (CNS) lymphoma, and there is hope that a significant proportion of patients will finally benefit. However, intensive efforts are needed to develop optimal screening tools, combinations, and sequences to explore the full potential of these new classes of therapeutic agents.
Insights
Novel immunotherapies targeting T cell checkpoints show promise for treating malignant lymphomas. Further research is essential to optimize these treatments for broader patient benefit.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Malignant lymphoma necessitates novel treatments due to patient mortality.
- Tumor cells evade immune surveillance, highlighting the need for immune augmentation.
- Understanding T cell regulation has led to checkpoint inhibitor development.
Purpose of the Study:
- To explore the potential of T cell checkpoint inhibitors in treating malignant lymphomas.
- To investigate the efficacy of these novel agents in various lymphoma subtypes.
Main Methods:
- Review of available data on checkpoint inhibitors in lymphoma treatment.
- Analysis of responses in Hodgkin's disease (HD) to inform non-Hodgkin's lymphoma (NHL) research.
Main Results:
- Checkpoint inhibitors demonstrate potential across diverse lymphoma entities.
- Positive responses observed in Hodgkin's disease suggest broader applicability.
- Specific lymphoma types like primary mediastinal B cell lymphoma (PMBCL) and central nervous system (CNS) lymphoma show promise.
Conclusions:
- Checkpoint inhibitors represent a promising therapeutic avenue for lymphoma patients.
- Optimizing screening tools, drug combinations, and treatment sequences is crucial.
- Further intensive research is required to fully realize the potential of these agents.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:31The Intrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:23Negative Regulator Molecules